These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 28471727)

  • 41. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM
    Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
    Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
    J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
    Hyams DM; Chan A; de Oliveira C; Snyder R; Vinholes J; Audeh MW; Alencar VM; Lombard J; Mookerjee B; Xu J; Brown K; Klein P
    Invest New Drugs; 2013 Oct; 31(5):1345-54. PubMed ID: 23801303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
    Yamamoto N; Nokihara H; Yamada Y; Goto Y; Tanioka M; Shibata T; Yamada K; Asahina H; Kawata T; Shi X; Tamura T
    Cancer Sci; 2012 Mar; 103(3):504-9. PubMed ID: 22145984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
    Chen E; Jonker D; Gauthier I; MacLean M; Wells J; Powers J; Seymour L
    Clin Cancer Res; 2009 Feb; 15(4):1481-6. PubMed ID: 19228749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
    Liu JF; Xiong N; Wenham RM; Wahner-Hendrickson A; Armstrong DK; Chan N; O'Malley DM; Lee JM; Penson RT; Cristea MC; Abbruzzese JL; Matsuo K; Olawaiye AB; Barry WT; Cheng SC; Polak M; Swisher EM; Shapiro GI; Kohn EC; Ivy SP; Matulonis UA
    Gynecol Oncol; 2024 Aug; 187():105-112. PubMed ID: 38759516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
    Fong PC; Boss DS; Yap TA; Tutt A; Wu P; Mergui-Roelvink M; Mortimer P; Swaisland H; Lau A; O'Connor MJ; Ashworth A; Carmichael J; Kaye SB; Schellens JH; de Bono JS
    N Engl J Med; 2009 Jul; 361(2):123-34. PubMed ID: 19553641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
    Hong DS; Garrido-Laguna I; Ekmekcioglu S; Falchook GS; Naing A; Wheler JJ; Fu S; Moulder SL; Piha-Paul S; Tsimberidou AM; Wen Y; Culotta KS; Anderes K; Davis DW; Liu W; George GC; Camacho LH; Percy Ivy S; Kurzrock R
    Cancer; 2014 Jul; 120(14):2164-73. PubMed ID: 24752867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Colombo N; Tomao F; Benedetti Panici P; Nicoletto MO; Tognon G; Bologna A; Lissoni AA; DeCensi A; Lapresa M; Mancari R; Palaia I; Tasca G; Tettamanzi F; Alvisi MF; Rulli E; Poli D; Carlucci L; Torri V; Fossati R; Biagioli E;
    Gynecol Oncol; 2022 Mar; 164(3):505-513. PubMed ID: 35063281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Lee JM; Peer CJ; Yu M; Amable L; Gordon N; Annunziata CM; Houston N; Goey AK; Sissung TM; Parker B; Minasian L; Chiou VL; Murphy RF; Widemann BC; Figg WD; Kohn EC
    Clin Cancer Res; 2017 Mar; 23(6):1397-1406. PubMed ID: 27663600
    [No Abstract]   [Full Text] [Related]  

  • 54. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
    Khan OA; Gore M; Lorigan P; Stone J; Greystoke A; Burke W; Carmichael J; Watson AJ; McGown G; Thorncroft M; Margison GP; Califano R; Larkin J; Wellman S; Middleton MR
    Br J Cancer; 2011 Mar; 104(5):750-5. PubMed ID: 21326243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    Kim JW; McKay RR; Radke MR; Zhao S; Taplin ME; Davis NB; Monk P; Appleman LJ; Lara PN; Vaishampayan UN; Zhang J; Paul AK; Bubley G; Van Allen EM; Unlu S; Huang Y; Loda M; Shapiro GI; Glazer PM; LoRusso PM; Ivy SP; Shyr Y; Swisher EM; Petrylak DP
    J Clin Oncol; 2023 Feb; 41(4):871-880. PubMed ID: 36256912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
    Sanborn RE; Hamid O; de Vries EG; Ott PA; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Cho DC; Plummer R; Stroh M; Lu L; Thistlethwaite F
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
    Satoh T; Yamada Y; Muro K; Hayashi H; Shimada Y; Takahari D; Taku K; Nakajima TE; Shi X; Brown KH; Boku N
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):439-46. PubMed ID: 21853311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
    Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
    J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Romero I; Rubio MJ; Medina M; Matias-Guiu X; Santacana M; Schoenenberger JA; Guerra EM; Cortés A; Minig L; Coronado P; Cueva JF; Gómez L; Malfettone A; Sampayo M; Llombart-Cussac A; Poveda A
    Gynecol Oncol; 2020 Dec; 159(3):721-731. PubMed ID: 32988624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.